Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial
Vaxxinity Inc (NASDAQ: VAXX) unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson's disease (PD).
UB-312 is a synthetic peptide vaccine targeting aggregated forms of aSyn, which plays a central role in PD development and progression.
UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the trial's primary objectives.
92% of patients (12 out of 13) who completed dosing with UB-312 developed anti-aSyn antibodies.
The results demonstrate important features for immunotherapy against PD and represent a proof-of-principle for Vaxxinity's platform in chronic disease.
UB-312 was well-tolerated, and antibodies were detectable in cerebrospinal fluid.
UB-312 safely broke immune tolerance, induced antibodies against toxic forms of alpha-synuclein, and showed potential target engagement in the periphery and crossing the blood-brain barrier.
The trial was not designed to measure differences in PD progression between UB-312 and placebo groups.
The Michael J. Fox Foundation is funding a collaborative project to evaluate the potential of UB-312 further and characterize the produced anti-aSyn antibodies.
Price Action: VAXX shares are down 2.38% at $2.05 on the last check Thursday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
